Bayer Intellectual Property GmbH, et al. v. Mankind Pharma Limited
| Bayer Intellectual Property GMBH, Bayer AG and Janssen Pharmaceuticals, Inc. |
| Mankind Pharma Limited |
| 1:2025cv01429 |
| November 24, 2025 |
| U.S. District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on January 14, 2026. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 12 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2. (Attachments: #1 Order)(aas) |
Filing 11
SO ORDERED Granting #10 Stipulation of Dismissal (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 1/14/2026. (aas)
|
| Filing 10 STIPULATION of Dismissal, by Bayer AG, Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 1/13/2026 (nms). |
|
SO ORDERED, re #9 STIPULATION and Proposed Order to Extend Time (*Reset Answer Deadlines: Mankind Pharma Limited answer due 1/30/2026). Signed by Judge Richard G. Andrews on 12/2/2025. (nms)
|
| Filing 9 STIPULATION and Proposed Order to Extend Time - filed by Bayer AG, Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 12/2/2025 (nms). |
| Filing 8 SUMMONS Returned Executed by Bayer Intellectual Property GMBH, Bayer AG, Janssen Pharmaceuticals, Inc..Mankind Pharma Limited served on 12/1/2025, answer due 12/22/2025. (Fahnestock, Derek) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (alb) |
| Remark: Notification sent to the MDL office of the above listed for inclusion of MDL 21-3017-RGA-LDH (mrr) |
| Filing 7 Summons Issued as to Mankind Pharma Limited on 11/24/2025. (mrr) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mrr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Intellectual Property GMBH filed by Bayer AG, Bayer Intellectual Property GmbH. (mrr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2. (mrr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/16/2025. Date of Expiration of Patent: U.S. Patent 9,539,218 expires February 17, 2034, with pediatric exclusivity to August 17, 2034.Thirty Month Stay Deadline: No earlier than 4/16/2028. (mrr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) |
| Filing 1 COMPLAINT against Mankind Pharma Limited (Filing fee $ 405, receipt number ADEDC-4845286) - filed by Bayer Intellectual Property GmbH, Bayer AG, Janssen Pharmaceuticals, Inc. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(mrr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
